Clinical trial · Observational
The Use of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular Carcinoma
Clinical Study of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on the clue that the serum marker AKR1B10 found in the investigators' previous study can be used as an effective indicator for detecting HCC and preHCC, the role and value of AKR1B10 as a new tumor marker for evaluating the recurrence monitoring of HCC after radical surgical resection needs further study, as to provide detailed clinical research data and scientific basis for improving the survival rate of HCC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention (observational study) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- post-operation recurrence or death
- timeFrame
- From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Meets the diagnostic criteria of primary hepatocellular carcinoma. * Meet the criteria for radical resection of hepatocellular carcinoma. * No anti-cancer treatment before the first diagnosis. Exclusion Criteria: * Patients who are pregnant or nursing. * Patients with incomplete clinical data, serological and imaging findings. * Patients who were lost to follow-up before the observation endpoint. * Complicated with serious heart, brain, lung, kidney, hematopoietic and other system diseases.
References
Publications (0)
Data not yet available